PepGen's DM1 Drug Cleared for Highest Dose; Cash Runway Extended into Q4 2027
PEPG has more than doubled off its 52-week low of $1.01.
Summary
PepGen's PGN-EDODM1 cleared to advance to the highest dose in its Phase 2 DM1 trial, with pivotal data due in November. Cash runway extended into Q4 2027.
Key Events · Product Development and Regulatory · PEPG
-
DSMB Clears Highest Dose Cohort
An independent Data and Safety Monitoring Board recommended advancing the Phase 2 FREEDOM2-DM1 study into the 12.5 mg/kg cohort with no protocol changes, and also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.
-
10 mg/kg Cohort Fully Enrolled
7 of 8 participants have completed dosing in the 10 mg/kg cohort; data from this cohort is expected in November 2026.
-
Cash Runway Extended into Q4 2027
Cash, cash equivalents, and marketable securities totaled $117.2 million as of June 30, 2026, sufficient to fund operations into the fourth quarter of 2027.
-
Q2 2026 Financial Results
Net loss was $17.8 million ($0.26 per share), with R&D expenses of $12.5 million and G&A of $6.4 million, both down from the prior year period.
Analysis · PEPG · Life Sciences
An independent safety board cleared PepGen's lead DM1 drug, PGN-EDODM1, to advance to the highest planned dose in its Phase 2 trial after reviewing data from the fully enrolled 10 mg/kg cohort. The DSMB also approved dose escalation in the open-label extension study. This removes a key clinical risk and keeps the program on track for a pivotal data readout in November. The company also reported a cash position of $117.2 million, extending its runway into the fourth quarter of 2027, which reduces near-term financing overhang.
At the time of this filing, PEPG was trading at $2.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $137M. The 52-week trading range was $1.01 to $7.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.